Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 10/20 | 0.54 |
| ▸ | REN | P00797 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | F2 | P00734 | 1/20 | 0.54 |
| ▸ | LTA4H | P09960 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | PEPD | P12955 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.54 |
| ▸ | HTR2A | P28223 | 1/20 | 0.54 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.54 |
| ▸ | HRH1 | P35367 | 1/20 | 0.54 |
| ▸ | THPO | P40225 | 1/20 | 0.54 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.54 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| N-Acetylproline SCHEMBL358379 | 1.00 | ACE (0.54) | ACERENLMNAHSD17B10CYP2C19 | |
| N-Acetylproline SCHEMBL428476 | 1.00 | ACE (0.54) | ACERENLMNAHSD17B10CYP2C19 | |
| N-Acetylproline SCHEMBL6469164 | 0.98 | ACE (0.53) | ACERENLMNAHSD17B10CYP2C19 | |
| N-Acetylproline SCHEMBL1375025 | 0.98 | ACE (0.53) | ACERENLMNAHSD17B10CYP2C19 | |
| N-Acetylproline SCHEMBL1375029 | 0.98 | ACE (0.53) | ACERENLMNAHSD17B10CYP2C19 | |
| SCHEMBL5860164 | 0.94 | ACE (0.49) | ACERENLMNAHSD17B10CYP2C19 | |
| SCHEMBL7054783 | 0.94 | ACE (0.49) | ACERENLMNAHSD17B10CYP2C19 | |
| SCHEMBL1840265 | 0.94 | ACE (0.49) | ACERENLMNAHSD17B10CYP2C19 | |
| SCHEMBL19566169 | 0.92 | ACE (0.56) | ACERENLMNAHSD17B10CYP2C19 | |
| SCHEMBL22423638 | 0.92 | ACE (0.56) | ACERENLMNAHSD17B10CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 519 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119517408-A | Method for establishing death prediction model of new-onset type 2 diabetes and application | 中南大学湘雅二医院 | 2025-02-25 | — | — | CN | claimed |
| CN-118542948-A | Nanometer medicinal preparation for treating sepsis, and its preparation method and application | 四川大学 | 2024-08-27 | — | — | CN | claimed |
| CN-116514679-A | Palladium-catalyzed sp with low-cost and high-efficiency quaternary ammonium nitrate as oxidant 2 And sp (sp) 3 Carbon hydrogen bond alkenylation method | 南京工业大学 | 2023-08-01 | — | — | CN | claimed |
| CN-113395898-A | Compositions for treating citrus disease and promoting yield enhancement of row crops | 斯波根生物技术公司 | 2021-09-14 | — | — | CN | claimed |
| EP-3546940-B1 | BIOMARKERS RELATED TO KIDNEY FUNCTION AND METHODS USING THE SAME | METABOLON INC (US) | 2021-02-17 | — | — | EP | claimed |
| EP-3039068-B1 | MOISTURE CURABLE COMPOUND WITH AMINO ACIDS | MOMENTIVE PERFORMANCE MAT INC (US) | 2020-12-16 | — | — | EP | claimed |
| CN-110997695-A | Novel compounds that activate the Nrf2 pathway | 阿尔米雷尔有限公司 | 2020-04-10 | — | — | CN | claimed |
| CN-110885358-A | Vaccine for preventing tumor recurrence and metastasis and application method thereof | 浙江爱睦世医学科技有限公司 | 2020-03-17 | — | — | CN | claimed |
| EP-3546940-A1 | BIOMARKERS RELATED TO KIDNEY FUNCTION AND METHODS USING THE SAME | Metabolon, Inc. (US) | 2019-10-02 | — | — | EP | claimed |
| US-20120214817-A1 | UROTENSIN II RECEPTOR ANTAGONISTS | MARYANOFF BRUCE E (US) | 2012-08-23 | — | — | US | claimed |
| US-6027890-A | DETECTING LIGAND BINDING BY INCUBATING TAGGED MEMBERS WITH BIOLOGICAL SAMPLE, SEPARATING BOUND FROM UNBOUND MEMBERS, CLEAVING TAG, THEN DETECTING BY NON-FLUORESCENT SPECTROSCOPY OR POTENTIOMETRY | RAPIGENE, INC. (US) | 2000-02-22 | — | — | US | claimed |
| EP-0962464-A2 | Methods and compositions for detecting binding of ligand pair using non-fluorescent label | Rapigene, Inc. (US) | 1999-12-08 | — | — | EP | claimed |
| EP-0722459-B1 | HEMOREGULATORY PENTA- OR HEXAPEPTIDES | NYCOMED IMAGING AS (NO) | 1998-12-23 | — | — | EP | claimed |
| EP-0868535-A2 | METHODS AND COMPOSITIONS FOR DETERMINING THE SEQUENCE OF NUCLEIC ACID MOLECULES | Rapigene, Inc. (US) | 1998-10-07 | — | — | EP | claimed |
| EP-0850320-A2 | METHODS AND COMPOSITIONS FOR DETECTING BINDING OF LIGAND PAIR USING NON-FLUORESCENT LABEL | DARWIN MOLECULAR CORPORATION (US) | 1998-07-01 | — | — | EP | claimed |
| WO-1997027331-A9 | METHODS AND COMPOSITIONS FOR DETERMINING THE SEQUENCE OF NUCLEIC ACID MOLECULES | — | 1997-10-09 | — | — | WO | claimed |
| WO-1997027331-A2 | METHODS AND COMPOSITIONS FOR DETERMINING THE SEQUENCE OF NUCLEIC ACID MOLECULES | RAPIGENE, INC. (US) | 1997-07-31 | — | — | WO | claimed |
| WO-1997027327-A2 | METHODS AND COMPOSITIONS FOR DETECTING BINDING OF LIGAND PAIR USING NON-FLUORESCENT LABEL | RAPIGENE, INC. (US) | 1997-07-31 | — | — | WO | claimed |
| EP-0508133-B1 | Method of preparation of L-Carnitine from D,L-Carnitine nitrile salts | DEGUSSA (DE) | 1995-02-15 | — | — | EP | claimed |
| US-5284872-A | Nitrato alkanoic acid derivatives, methods for their production, pharmaceutical compositions containing the derivatives and medicinal uses thereof | SCHWARZ PHARMA AG (DE) | 1994-02-08 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214817-A1 | UROTENSIN II RECEPTOR ANTAGONISTS | UTS2R, PLAUR, BDKRB2 | ACE 120/4885REN 31/4885LMNA 2503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.